Novartis is a research-based pharmaceutical company. Every day, we work to reimagine medicine with the goal of improving and extending people’s lives, empowering patients, healthcare professionals, and communities as they confront serious and complex diseases. Novartis medications reach more than 250 million people worldwide.
As part of this vision, Novartis emphasizes the power of innovation as a central pillar of its work—not only in developing advanced therapies, but also in fostering broad, long-term collaborations across the entire healthcare ecosystem.
Novartis believes in the Triple Win approach, which seeks meaningful benefits in every partnership for all stakeholders in the healthcare system, first and foremost for patients.
Novartis develops treatments in four core disease areas: oncology and hemato-oncology, cardiovascular and renal diseases, immunology, and neurology. Novartis Israel values the work of Haverim L’Refuah on behalf of patients in Israel and views it as a reflection of shared values—commitment to patients, access to treatment, and social responsibility.
Elad Maron
CEO, Novartis Israel Ltd.
